Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab

Journal of Neuro-Oncology

Volumn 119, Issue 1, 2014, Pages 149-158

  Rahman, Rifaquat ^a   Hamdan, Alhafidz ^b   Zweifler, Rebecca ^b   Jiang, Han ^b   Norden, Andrew D ^b   Reardon, David A ^b   Mukundan, Srinivasan ^b   Wen, Patrick Y ^b   Huang, Raymond Y ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Apparent diffusion coefficient; Bevacizumab; Glioblastoma; Survival analysis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; IRINOTECAN; LOMUSTINE; PANOBINOSTAT; PLERIXAFOR; STEROID; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PATIENT CODING; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; T1 WEIGHTED IMAGING; T2 FLAIR IMAGING; TUMOR VOLUME; BRAIN NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR BURDEN; YOUNG ADULT;

EID: 84906933717     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1464-8     Document Type: Article

References (24)

1. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92:149-155
2. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27:740-745
3. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27:4733-4740
4. Yamasaki F, Kurisu K, Satoh K et al (2005) Apparent diffusion coefficient of human brain tumors at MR Imaging1. Radiology 235:985-991 (Pubitemid 40695898)
5. Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D (2004) Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted mr imaging and diffusion-tensor MR Imaging1. Radiology 232:451-460 (Pubitemid 38971286)
6. Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging JMRI 9:53-60 (Pubitemid 29068231)
7. Pope WB, Lai A, Mehta R et al (2011) Apparent diffusion coefficent histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. doi:10.3174/ajnr.A2385
8. Pope WB, Kim HJ, Huo J et al (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182-189
9. Pope WB, Qiao XJ, Kim HJ et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108:491-498
10. Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM (2011) Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 102:95-103
11. Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB (2011) Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology 13:1151-1161
12. Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D, Mikkelsen T (2010) Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 96:423-431
13. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ (2009) Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol 91:69-81
14. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ (2009) Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol 91:337-351
15. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol Off J Am Soc Clin Oncol 28:1963-1972
16. Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY (2013) Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. doi:10.1002/cncr.28210
17. Pieper S, Lorensen B, Schroeder W et al. (2006) The NA-MIC Kit: ITK, VTK, pipelines, grids and 3D slicer as an open platform for the medical image computing community. In: 3rd IEEE International Symposium on Biomedical Imaging: Macro to Nano, 2006, pp 698-701.24
18. Pieper S, Halle M, Kikinis R (2004) 3D SLICER. Proceedings of the 1st IEEE International Symposium on Biomedical Imaging: from Nano to Macro 2004, pp 632-635
19. Provenzale JM, Mukundan S, Barboriak DP (2006) Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 239:632-649 (Pubitemid 43830599)
20. Morita K, Matsuzawa H, Fujii Y, Tanaka R, Kwee IL, Nakada T (2005) Diffusion tensor analysis of peritumoral edema using lambda chart analysis indicative of the heterogeneity of the microstructure within edema. J Neurosurg 102:336-341 (Pubitemid 43194085)
21. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
22. Gerstner ER, Frosch MP, Batchelor TT (2009) Diffusion magnetic resonance imaging detects pathologically confirmed, non-enhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 28:e91-e93
23. Rieger J, Bähr O, Müller K, Franz K, Steinbach J, Hattingen E (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99:49-56
24. Kang Y, Choi SH, Kim Y-J, Kim KG, Sohn C-H, Kim J-H, Yun TJ, Chang K-H (2011) Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted mr imaging - correlation with tumor grade. Radiology 261:882-890